NCT07764588Recruiting
Innate Immune Cell Phenotypes and Early Fibrotic Repair in Acute Myocardial Infarction
Source: ClinicalTrials.gov · Last updated 14 Aug 2026
Brief summary (registry, in English)
To determine the relationship of the phenotypes of neutrophils and monocytes with early fibrotic repair after acute myocardial infarction.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 10 Aug 2026
- Start date
- 1 Jan 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Shanghai 10th People's Hospital
- Diseases
- Coronary artery disease
- NCT number
- NCT07764588
What you commit to
- Study type: Observational
- Planned participants: 50
- From 1 Jan 2026 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior revascularization
- Metallic implants or claustrophobia that precluded MRI
Other illness
- Known allergy to gadopentetate dimeglumine contrast agent
Lab values
- Severe hepatic or renal dysfunction (ALT \> 5×ULN or eGFR \< 15 mL/min/1.73 m²)
Other
- Pregnancy or planned pregnancy within the next 6 months
- Life expectancy \< 1 year
- Severe COPD or inability to hold breath for MRI
Who the study is looking for
- \---- Age \> 18 and ≤ 80 years old
- \- Patients with acute STEMI within 12 hours of symptom onset who are planned to receive PPCI
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai Tenth People's Hospital Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.